#TalkingRegMed episode 6: Brexit with Matthew Durdy, Cell and Gene Therapy Catapult
In this episode of #TalkingRegMed, Matthew Durdy, Chief Business Officer, Cell and Gene Therapy Catapult, explains the effect of Brexit on cell therapy development in the UK.
Please sign in or register for FREE
Sign in to RegMedNet
Register to RegMedNet
RegMedNet is a free content and networking hub promoting global connection, knowledge-sharing and collaboration between all members of the regenerative medicine field.